Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Immune Thrombocytopenic Purpura (ITP): later-stage trial registry
2 of 3 indexed Immune Thrombocytopenic Purpura (ITP) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Immune Thrombocytopenic Purpura (ITP): 3 US clinical trials tracked, 2 recruiting.
Immune Thrombocytopenic Purpura (ITP) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 2 of these trials.
Enrollment posture brief
Registry condition immune-thrombocytopenic-purpura-itp
OPEN 2 | RECR 67% | LATE 2 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Immune Thrombocytopenic Purpura (ITP) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Immune Thrombocytopenic Purpura (ITP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Immune Thrombocytopenic Purpura (ITP) is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Takeda
NCT06722235
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Takeda
NCT06948318
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
Novartis Pharmaceuticals
NCT03524612
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Immune Thrombocytopenic Purpura (ITP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Immune Thrombocytopenic Purpura (ITP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Immune Thrombocytopenic Purpura (ITP) page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Immune Thrombocytopenic Purpura (ITP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Takeda sponsors the most Immune Thrombocytopenic Purpura (ITP) trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immune Thrombocytopenic Purpura (ITP) condition card totals 3 registered trials; most-linked intervention Mezagitamab; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.